Abnormal eicosanoid pattern by blood leukocytes in gastroduodenal ulcer

Medical Science Monitor

Volumn 10, Issue 10, 2004, Pages

  Baenkler, Hanns W ^a   Zeus, Jürgen ^b   Schenk, Jürgen ^b   Schäfer, Dirk ^a,c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b Gastroenterol Gemeinschaftspraxis   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Blood leukocytes; Eicosanolds; Gastroduodenal ulcer; Leukotrienes; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; ICOSANOID; LEUKOTRIENE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN; PROSTAGLANDIN E2;

AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ENZYME IMMUNOASSAY; FEMALE; GASTRODUODENAL ULCER; HUMAN; ICOSANOID METABOLISM; IMMUNE RESPONSE; INFLAMMATORY CELL; LEUKOCYTE; MALE; PATHOPHYSIOLOGY; PROSTAGLANDIN SYNTHESIS; RISK ASSESSMENT;

EICOSANOIDS; FEMALE; HEALTH; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; PEPTIC ULCER;

EID: 7044273985     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Smith DL, Willis AL: A suggested shorthand nomenclature for eicosanoids. Lipids, 1987; 22: 983-86
2. Murray JL, Dowd J, Hersh EM: In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin. J Biol Response Mod, 1986; 5: 12-19
3. Phipps RS, Stein SH, Roper RL: A new view of prostaglandin E regulation of immune response. Immunology Today, 1991; 12: 349-52
4. Lala PK, Parhar RS, Singh P: Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cell Immunol, 1986; 99: 108-18
5. Samuelsson B: Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science, 1983; 220: 568-75
6. Baenkler HW, Schäfer D, Hosemann W: Eicosanoids of normal and polypous nasal mucosa. Rhinology, 1996; 34: 166-70
7. Schäfer D, Lindenthal U, Wagner M et al: Effects of prostaglandin E2 on eicosanoid release by bronchial biopsy specimens from normal and inflamed mucosa. Thorax, 1996; 56: 919-23
8. Schäfer D, Schmid M, Göde U, Baenkler HW: Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics. Eur Resp J, 1999; 13: 638-46
9. Gosepath J, Schäfer D, Mann WJ: Analgetika-Intoleranz: Langzeitergebnisse bis zu 3 Jahren bei adaptativer Desaktivierung mit einer täglichen Erhaltungsdosis von 100 mg Aspirin. Laryngo-Rhino-Otol, 2002; 81: 732-38
10. Schmid M, Göde U, Schäfer D, Wigand M: Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics. Acta Otolaryngol (Stockh), 1999; 119: 277-80
11. Gospath J, Hoffmann F, Schäfer D et al: Aspirin intolerance in patients with chronic sinusitis. ORL J Otorhinolaryngol Relat Spec, 1999; 61: 146-50
12. Tseng GY, Lin HJ, Lin HY et al: Effect of nonsteroidal anti-inflammatory drugs on gastric and duodenal prostaglandin concentrations in patients with Helicobacter pylori infection. Hepathogastroenterology, 1999; 46: 1000-4
13. Chan FK: Helicobacter pylori, NSAIDs and gastrointestinal haemorrhage. Eur J Gastroenterol Hepatol, 2002; 14: 1-3
14. Barkin J: The relation between Helicobacter pylori and nonsteroidal anti-inflammatory drugs. Am J Med, 1998; 105(5A); 22S-27S
15. Lazzaroni M, Poro GB: Nonsteroidal anti-inflammatory drug gastropathy and Helicobacter pylori: the search for an improbable consensus. Am J Med, 2001; 110 (1A): 50S-54S
16. Laine L, Cominelli F, Sloane R et al: Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double blind trial. Aliment Pharmacol Ther ,1995; 9: 127-35
17. Chan FK: COX-2 inhibition, H. pylori infection and the risk of gastrointestinal complications. Curr Pharm Des, 2003; 9(27): 2213-19
18. Jackson LM, Wu KC, Mahida YR et al: Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa. Gut, 2000; 47 (6): 762-70
19. Feldman M, Cryer B, Mallat D, Go MF: Role of Helicobacter pylori infection in gastroduodenal injury and gastric prostaglandin synthesis during long term/low dose aspirin therapy: a prospective placebo-controlled, double-blind randomized trial. Am J Gastroenterol, 2001; 96: 1751-57
20. Kaldenbach T, Schäfer D, Gosepath J et al: Die Bedeutung eosinophiler Granulocyten in Beziehung zu Allergie und Aspirin-Intolerenz bei Patienten mit Sinusitis polyposa. Laryngo Rhino Otol, 1999; 78: 429-34
21. Karttunen R, Andersson G, Poikonen K et al: Helicobacter pylori induces lymphocyte activation in peripheral blood culture. Clin Exp Immunol, 1990; 82: 485-88
22. Nielsen H, Andersen LP: Activation of human phagocyte oxidative metabolism by Helicobacter pylori. Gastroenterology, 1992; 103: 1747-53
23. Craig PM, Territo MC, Karnes WE: Helicobacter pylori secretes a chemotactic factor for monocytes and neutrophils. Gut, 1992; 33: 1020-23
24. Satin B, Del Guidice G, Delia Bianca V et al: The neutrophil-activating protein (HP-NAP) of Helicobacter pylori is a protective antigen and a major virulence factor. J Exp Med, 2000; 191(9): 1467-76